Kyle Lahucik

Abcuro has collected $66 million a few months after saying its sole drug missed the mark in inclusion body myositis, but had found hope in a subset of patients with less severe forms.

Redx Pharma merges with Skye Bioscience via reverse merger, rebranding as Fibrx Therapeutics on Nasdaq, raising $125M to advance ROCK inhibitor RXC008 for Crohn's disease.

OmniAb/Lilly ion channel deal ($370M); Slate/Fulcrum reverse merger ($245M PIPE); AbelZeta regains C-CAR039 rights; Leal's $30M Series A; Aizen's AI peptide deal.

Reverse mergers are having their biggest year since 2018, with 17 deals in 2026 as bankers expect the trend — led by Avere's $820M raise — to keep accelerating.

The California biopharma is paying $275 million upfront to acquire a rare bone disease asset from Alesta Therapeutics, codenamed ALE1.

→ Fresh off a new accelerated approval for its melanoma therapy, Replimune has named Michelle DiNapoli as chief commercial officer …

Ambros Therapeutics will take the Nasdaq spot of Werewolf Therapeutics, a cancer biotech that has been exploring strategic alternatives for most of this year, the companies said Friday morning.

J&J-Sail and AbbVie-Kestrel put a spotlight on the option-to-acquire structure — rare even in a record M&A year — with biotech and pharma leaders weighing its risk-sharing appeal against its wrinkles.

Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a $1.5B+ deal for ex-China rights to a type 2 inflammatory disease drug.

Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.